Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EPS (Weighted Average and Diluted) (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.42 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 60.0% to -$0.42 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.21, a 35.15% increase, with the full-year FY2025 number at -$3.84, up 29.93% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.42 in Q4 2025 for Enanta Pharmaceuticals, up from -$0.88 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.42 in Q4 2025 to a low of -$1.86 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.3 (2022), compared with a mean of -$1.28.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 263.33% in 2021 and later skyrocketed 60.0% in 2025.
  • Enanta Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.48 in 2021, then increased by 6.08% to -$1.39 in 2022, then fell by 13.67% to -$1.58 in 2023, then skyrocketed by 33.54% to -$1.05 in 2024, then skyrocketed by 60.0% to -$0.42 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.42 (Q4 2025), -$0.88 (Q3 2025), and -$0.85 (Q2 2025) per Business Quant data.